InvestorsHub Logo

Monk44

09/22/20 8:57 PM

#300813 RE: Larrybirdlegend #300810

LBL
There you go making sense again!
Rationality is what we need to get through this.
This will be in my daily read of positivity

ilovetech

09/22/20 9:00 PM

#300815 RE: Larrybirdlegend #300810

LBD., great post, period.

ILT

Number sleven

09/22/20 9:02 PM

#300816 RE: Larrybirdlegend #300810

LBL, Thank you for posting. A non emotional evaluation of our situation.
Sleven,

MontanaState83

09/22/20 9:22 PM

#300822 RE: Larrybirdlegend #300810

LBL - pardon my ignorance but label rewrite? Combo pill?

xblkbk

09/22/20 9:41 PM

#300829 RE: Larrybirdlegend #300810

Totally agree, thanks LBL!!

And yes, $7-$10 is way too low!!

Whalatane

09/23/20 1:37 AM

#300843 RE: Larrybirdlegend #300810

LBL ..so to some of your pts
1) Unlikely legal action gets anywhere
2)Branded generic V will not make AMRN any $ ....agreeing to supply Apotex for their generic Vascepa .. with the product or the API supply via their existing supply agreements with Nisshan ? might .
3) OTC and branded combo are NOT going to work.
4) Hikma will have 180 day exclusivity ...first mover advantage so harder for other generic to carve out a market of any size
5) 800 sales reps still have their jobs ....yep until Hikma demonstrates they have the API supply and can scale up.
6) Baker Bros will wait for the EU market or a buy out offer to appear .

Actual rather than a " sell the news " day ....the day Hikma launches might be a " buy the news "type of day

Kiwi